SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO)
PR Newswire
NEW YORK, July 27, 2026
NEW YORK, July 27, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Abeona Therapeutics Inc. (NASDAQ: ABEO) on behalf of the company's shareholders. The investigation seeks to determine whether Abeona Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.
If you are a shareholder of Abeona Therapeutics and are interested in obtaining additional information about your rights and options, please visit us at: https://pjlfirm.com/abeona-therapeutics-inc/
You may also contact Robert H. Lefkowitz, Esq. either via email at rl@pjlfirm.com or by telephone at 212-725-1000. One of our attorneys will personally speak with you about the case at no cost or obligation.
Purcell & Lefkowitz LLP is a law firm exclusively committed to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty and other types of corporate misconduct. For more information about the firm and its attorneys, please visit https://pjlfirm.com. Attorney advertising. Prior results do not guarantee a similar outcome.
SOURCE Purcell & Lefkowitz LLP
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States